Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis

Lopci, Egesta; Lughezzani, Giovanni; Castello, Angelo; Saita, Alberto; Colombo, Piergiuseppe; Hurle, Rodolfo; Peschechera, Roberto; Benetti, Alessio; Zandegiacomo, Silvia; Pasini, Luisa; Casale, Paolo; Diana, Pietro; Bevilacqua, Giulio; Balzarini, Luca; Buffi, Nicolò Maria; Guazzoni, Giorgio; Lazzeri, Massimo

doi:10.1016/j.euf.2020.03.004

Cited by 38 publications

(54 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chance of a false positive lesion is lower in a population of men with proven prostate cancer, than in a mixed population composed of both men with prostate cancer and without. However, Lopci et al showed high specificity of 90% in a mixed population as well [30]. They performed PSMA-guided biopsies.…”

Section: Discussionmentioning

confidence: 99%

Detection and Local Staging of Prostate Cancer by 68Ga-PSMA-PET/CT, Comparison with mpMRI and Histopathology

Intema¹,

Kooistra²,

Vermeulen³

et al. 2020

AMI

View full text Add to dashboard Cite

Introduction: 68Ga-PSMA-PET/CT has proven its value in prostate cancer with high positive predictive value for lymph node metastasis and superior detection of distant metastasis. There is growing evidence that 68Ga-PSMA-PET/CT has high sensitivity for detection of tumor lesions in the prostate as well. Studies thus far have mainly been performed in patients prior to prostatectomy. Aim of this study is to evaluate diagnostic accuracy in a mixed population of men with increased risk of prostate cancer and evaluate diagnostic possibilities with respect to extra-capsular extension and seminal vesicle invasion. Methods: The population consisted of a retrospectively included sequential cohort of 69 patients with 68Ga-PSMA-PET/CT and mpMRI available. 68Ga-PSMA-PET/CT was re-evaluated by two readers blinded for mpMRI and clinical information. Likelihood of tumour presence, extra-prostatic extension and seminal vesicle invasion was scored on 5-point Likert scale and localized schematically. Results were compared with mpMRI. Available pathological outcome served as gold standard. SUVmax of index lesions was measured and correlated to index tumor Gleason grade. Results: Clinically significant prostate cancer (Gleason ≥ 3 + 4) was detected in 57 (83%) of 69 patients. Diagnostic accuracy was 89% for PET reader 1, 93% for PET reader 2 and 86% for mpMRI. Lesion concordance of 68Ga-PSMA-PET/CT and mpMRI was 97%. SUVmax of the index lesion correlated to Gleason grade.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection and Local Staging of Prostate Cancer by 68Ga-PSMA-PET/CT, Comparison with mpMRI and Histopathology

Intema¹,

Kooistra²,

Vermeulen³

et al. 2020

AMI

View full text Add to dashboard Cite

show abstract

“…Both fluciclovine and PSMA radiotracers have been studied in detection and staging of treatment-naïve prostate cancer and show potential. 10 , 29 , 48 – 51 Fluciclovine-guided biopsies for recurrent prostate cancer have been studied and the approach is feasible, improving on template biopsy alone. 52 , 53 Similar work has been done with PSMA radiotracers, including the PRIMARY trial, which demonstrated that inclusion of PSMA-PET in biopsy guidance led to improved negative predictive value compared with mpMRI alone.…”

Section: Use Of Pet For Targeted Biopsy Guidancementioning

confidence: 99%

Role of molecular imaging in the detection of localized prostate cancer

Galgano

West

Rais‐Bahrami

2022

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Molecular imaging of prostate cancer continues to grow, with recent inclusion of several positron emission tomography (PET) radiotracers into the recent National Comprehensive Cancer Network guidelines and the US Food and Drug Administration approval of prostate-specific membrane antigen (PSMA)-targeted radiotracers. While much of the work for many of these radiotracers is focused on systemic staging and restaging in both newly diagnosed high-risk prostate cancer and biochemically recurrent disease patients, the potential role of molecular imaging for the detection of localized prostate cancer has not yet been fully established. The primary aim of this article will be to present the potential role for molecular imaging in the detection of localized prostate cancer and discuss potential advantages and disadvantages to utilization of both PET/computed tomography (CT) and PET/magnetic resonance imaging (MRI) for this clinical indication of use.

show abstract

“…A targeted fusion prostate biopsy was carried out in 64 patients who had PET-positive areas, and clinically significant PCa was detected in 36% (n = 23) of these patients. The authors concluded that Ga-68 PSMA-PET/CT would be sufficient to detect clinically significant PCa in cases where PCa suspicion continues despite a negative initial biopsy (16). In another study in which 21 high-risk PCa cases were evaluated for primary staging, conventional imaging methods and PSMA-PET imaging were compared in terms of their diagnostic accuracy.…”

Section: Role Of Psma-pet/ct In Tumor Stagingmentioning

confidence: 99%

Is it time to stage prostate cancer using molecular imaging?

Güzel¹,

POLAT²,

ATAN³

2022

New J Urol.

View full text Add to dashboard Cite

Prostate cancer is one of the most common cancers in men. After the diagnosis is made, staging should be undertaken with imaging methods in order to plan the treatment and predict the prognosis. Parallel to technological developments in recent years, new imaging methods have entered into clinical use. Among these methods, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has come to the fore since it provides anatomical and functional imaging and has many advantages in tumor (T), nodal (N) and metastatic (M) staging. This review discusses the current status of the PSMA- PET method in prostate cancer staging. Keywords: prostate cancer, staging, positron emission tomography

show abstract

Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis

Cited by 38 publications

References 31 publications

Detection and Local Staging of Prostate Cancer by 68Ga-PSMA-PET/CT, Comparison with mpMRI and Histopathology

Detection and Local Staging of Prostate Cancer by 68Ga-PSMA-PET/CT, Comparison with mpMRI and Histopathology

Role of molecular imaging in the detection of localized prostate cancer

Is it time to stage prostate cancer using molecular imaging?

Contact Info

Product

Resources

About